Revance Therapeutics (NASDAQ:RVNC) reported its Q2 earnings results on Tuesday, August 9, 2022 at 04:00 PM.
Here’s what investors need to know about the announcement.
Earnings
Revance Therapeutics missed estimated earnings by 2.33%, reporting an EPS of $-0.88 versus an estimate of $-0.86.
Revenue was up $9.56 million from the same period last year.
Past Earnings Performance
Last quarter the company missed on EPS by $0.03 which was followed by a 11.04% drop in the share price the next day.
Here’s a look at Revance Therapeutics’s past performance:
| Quarter | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 |
|---|---|---|---|---|
| EPS Estimate | -0.91 | -1.02 | -1.15 | -1.05 |
| EPS Actual | -0.94 | -0.93 | -1.10 | -1.07 |
| Revenue Estimate | 24.01M | 24.27M | 20.29M | 15.48M |
| Revenue Actual | 25.26M | 25.95M | 19.75M | 18.80M |
To track all earnings releases for Revance Therapeutics visit their earnings calendar here.
This article was generated by Benzinga’s automated content engine and reviewed by an editor.
